Experimental UC drug trial halted early – what we know

NCT ID NCT07029971

Terminated Disease control Sponsor: Vial Australia Pty Ltd Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial tested a new antibody drug (BB-TL1A-VIAL-HLE) in 16 healthy volunteers and people with moderate-to-severe ulcerative colitis. The goal was to check safety and see if it could improve colon inflammation. However, the study was terminated early, so we have limited information on whether it works or is safe.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: BB-TL1A-VIAL-HLE (an antibody targeting TL1A)
What this could lead to: If it works, this could point toward a new treatment option for people with moderate-to-severe ulcerative colitis.
What could go wrong: This was a very early (phase 1) trial that was terminated, so we don't know if the drug is safe or effective. The small size (16 people) and early termination mean results are uncertain.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ULCERATIVE COLITIS (UC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

ulcerative colitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ULCERATIVE COLITIS (UC)

Contacts and locations

Locations

Arcadia Pittwater Private Hospital (Operated by Battery Bio)

Warriewood, New South Wales, 2102, Australia
Dymocks Building, WellShare Site

Sydney, New South Wales, 2000, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.